F2G Ltd

The US Food and Drug Administration maintained a high rate of complete response letter actions for novel agent applications in 2024, but recent history suggests that many of the 16 CRL recipients will

Bain Capital Life Sciences (BCLS) raised its largest investment fund yet, nearly doubling the amount of money it has at its disposal to back both private and public drug developers, medical device and

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

Eiger BioPharmaceuticals, Inc. ’s peginterferon lambda, Gilead Sciences, Inc. ’s magrolimab, Takeda Pharmaceutical Co. Ltd. ’s TAK-994 and Bavarian Nordic A/S ’s RSV vaccine are the latest entrants